Streetbeat News

Price Targets

TEX

Analysts have mixed views on Terex (NYSE:TEX), with recent ratings ranging from bullish to bearish. The average 12-month price target is $62.86, up from $61.00, with actions including raises and lowers by notable firms. Terex's financials show positive revenue growth, high net margin, and strong ROE and ROA, with a lower-than-average debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 12:01 pm

AESI

Goldman Sachs analyst Neil Mehta reinstated Atlas Energy Solutions (AESI) with a Buy rating and set a price target of $24.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 12:00 pm

AEE

Recent evaluations by 5 financial analysts on Ameren (NYSE:AEE) show diverse outlooks, with an average 12-month price target of $74.2, reflecting a slight increase from the previous target. Analyst actions include ratings adjustments and price target changes, indicating varied perspectives on Ameren's performance. Despite facing revenue challenges and below-average profitability metrics, Ameren's market position remains robust, supported by its significant market capitalization and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 12:00 pm

PLMR

In the last three months, 4 analysts have updated their ratings on Palomar Holdings (NASDAQ:PLMR), showing a shift towards a more bullish outlook. The average 12-month price target has been raised to $82.75, up 14.53% from the previous $72.25. Analysts from Jefferies, Keefe, Bruyette & Woods, Truist Securities, and Evercore ISI Group have all raised their price targets, indicating a positive sentiment towards PLMR's market position and financial health, highlighted by its revenue growth, net margin, and ROE.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 12:00 pm

SIRI

Guggenheim analyst Curry Baker has initiated coverage on Sirius XM Holdings (NASDAQ:SIRI) with a Neutral rating and set a price target of $4.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:58 am

SLN

Chardan Capital analyst Keay Nakae has maintained a Buy rating on Silence Therapeutics (NASDAQ:SLN) and increased the price target from $26 to $42.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:54 am

MIRM

Mirum Pharmaceuticals' shares surged following the FDA's approval of LIVMARLI oral solution for treating cholestatic pruritus in patients aged five and older with progressive familial intrahepatic cholestasis. Additionally, HC Wainwright reaffirmed a Buy rating on MIRM and increased its price target from $45 to $58.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:54 am

FTCI

HC Wainwright & Co. analyst Amit Dayal maintains a Buy rating on FTC Solar (NASDAQ:FTCI) but lowers the price target from $2.5 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:53 am

S

Loop Capital analyst Yun Kim maintains a Buy rating on SentinelOne (NYSE:S) and raises the price target from $28 to $30.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:53 am

SHLT

Litchfield Hills analyst Theodore O'Neill initiates coverage on SHL Telemedicine (NASDAQ:SHLT) with a Buy rating and a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:51 am